ATOSSA THERAPEUTICS, INC.: current assets
Current assets for ATOSSA THERAPEUTICS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All ATOSSA THERAPEUTICS, INC. financial histories
What this measure means
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
Exact concept: us-gaap:AssetsCurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2011-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 45,618,000 | USD | 2026-03-25 | 10-K · 0001193125-26-124396 |
| At date | 2024-12-31 | 74,457,000 | USD | 2026-03-25 | 10-K · 0001193125-26-124396 |
| At date | 2023-12-31 | 92,219,000 | USD | 2025-03-25 | 10-K · 0000950170-25-044099 |
| At date | 2022-12-31 | 118,197,000 | USD | 2024-04-01 | 10-K · 0000950170-24-039306 |
| At date | 2021-12-31 | 141,240,000 | USD | 2023-03-22 | 10-K · 0001437749-23-007531 |
| At date | 2020-12-31 | 42,770,000 | USD | 2022-02-28 | 10-K · 0001437749-22-004614 |
| At date | 2019-12-31 | 14,319,266 | USD | 2021-03-31 | 10-K · 0001437749-21-007756 |
| At date | 2018-12-31 | 11,549,366 | USD | 2020-03-26 | 10-K · 0001437749-20-006155 |
| At date | 2017-12-31 | 7,898,034 | USD | 2019-03-28 | 10-K · 0001437749-19-005927 |
| At date | 2016-12-31 | 3,254,563 | USD | 2018-03-08 | 10-K · 0001615774-18-001693 |
| At date | 2015-12-31 | 4,294,851 | USD | 2017-03-21 | 10-K/A · 0001615774-17-001151 |
| At date | 2014-12-31 | 9,340,197 | USD | 2016-03-30 | 10-K · 0001144204-16-091380 |
| At date | 2013-12-31 | 6,761,860 | USD | 2015-03-30 | 10-K · 0001144204-15-019344 |
| At date | 2012-12-31 | 1,989,496 | USD | 2014-03-27 | 10-K · 0001144204-14-018247 |
| At date | 2011-12-31 | 2,945,429 | USD | 2013-03-28 | 10-K · 0001144204-13-018024 |
Related financial histories
- ATOSSA THERAPEUTICS, INC.: total assets
- ATOSSA THERAPEUTICS, INC.: total liabilities
- ATOSSA THERAPEUTICS, INC.: stockholders equity
- ATOSSA THERAPEUTICS, INC.: cash and cash equivalents
- ATOSSA THERAPEUTICS, INC.: net income or loss
- ATOSSA THERAPEUTICS, INC.: operating cash flow
- ATOSSA THERAPEUTICS, INC.: capital expenditure payments
- ATOSSA THERAPEUTICS, INC.: financing cash flow
- ATOSSA THERAPEUTICS, INC.: investing cash flow
- ATOSSA THERAPEUTICS, INC.: retained earnings or deficit
- ATOSSA THERAPEUTICS, INC.: basic weighted-average shares
- ATOSSA THERAPEUTICS, INC.: diluted weighted-average shares
- ATOSSA THERAPEUTICS, INC.: basic earnings per share
- ATOSSA THERAPEUTICS, INC.: diluted earnings per share
- ATOSSA THERAPEUTICS, INC.: net property, plant and equipment
- ATOSSA THERAPEUTICS, INC.: share-based compensation expense
- ATOSSA THERAPEUTICS, INC.: operating income or loss
- ATOSSA THERAPEUTICS, INC.: interest expense
- ATOSSA THERAPEUTICS, INC.: current liabilities
- ATOSSA THERAPEUTICS, INC.: current accounts payable
- ATOSSA THERAPEUTICS, INC.: net finite-lived intangible assets
- ATOSSA THERAPEUTICS, INC.: net current accounts receivable
- ATOSSA THERAPEUTICS, INC.: common-stock repurchase payments
- ATOSSA THERAPEUTICS, INC.: operating expenses
- ATOSSA THERAPEUTICS, INC.: net inventory
- ATOSSA THERAPEUTICS, INC.: gross profit
- ATOSSA THERAPEUTICS, INC.: cost of revenue
- ATOSSA THERAPEUTICS, INC.: research and development expense
Inspect the source
- Entity
- ATOSSA THERAPEUTICS, INC. / CIK 0001488039
- Captured
- 2026-09-20T09:09:43.864Z
- SEC response SHA-256
1a9a7394baaf8eaa5fbb9f56ff3e675865210f784ada942417e365f62ac259f6
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001488039.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))